Previous close | 1,705.20 |
Open | 1,701.60 |
Bid | 1,705.80 x 0 |
Ask | 1,706.20 x 0 |
Day's range | 1,699.21 - 1,709.60 |
52-week range | 1,302.60 - 1,725.81 |
Volume | |
Avg. volume | 9,139,472 |
Market cap | 69.725B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 14.22 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.64 (3.75%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.
Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...
In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]